Barrington Research Has Bullish Outlook for MMSI Q3 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Investment analysts at Barrington Research raised their Q3 2025 EPS estimates for Merit Medical Systems in a research note issued to investors on Wednesday, January 29th. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will earn $0.96 per share for the quarter, up from their prior estimate of $0.95. Barrington Research has a “Outperform” rating and a $115.00 price target on the stock. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Barrington Research also issued estimates for Merit Medical Systems’ Q4 2025 earnings at $0.94 EPS, FY2025 earnings at $3.82 EPS and FY2026 earnings at $4.30 EPS.

Several other research firms have also recently commented on MMSI. Needham & Company LLC lifted their target price on Merit Medical Systems from $109.00 to $122.00 and gave the company a “buy” rating in a research note on Wednesday. Raymond James increased their price objective on shares of Merit Medical Systems from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 31st. StockNews.com downgraded Merit Medical Systems from a “buy” rating to a “hold” rating in a research report on Sunday, November 3rd. Robert W. Baird raised their price target on Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, Piper Sandler reissued an “overweight” rating and set a $116.00 target price (up from $114.00) on shares of Merit Medical Systems in a report on Wednesday. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $109.80.

Merit Medical Systems Price Performance

Shares of Merit Medical Systems stock opened at $108.88 on Thursday. Merit Medical Systems has a 1-year low of $70.70 and a 1-year high of $111.45. The firm’s 50-day moving average price is $101.47 and its two-hundred day moving average price is $97.13. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $6.35 billion, a price-to-earnings ratio of 53.37, a P/E/G ratio of 2.42 and a beta of 0.85.

Merit Medical Systems (NASDAQ:MMSI) last issued its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The business had revenue of $339.85 million for the quarter, compared to analyst estimates of $334.60 million. During the same period in the previous year, the business earned $0.75 EPS. The firm’s revenue was up 7.8% on a year-over-year basis.

Institutional Trading of Merit Medical Systems

Institutional investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its stake in Merit Medical Systems by 305.4% during the 3rd quarter. Barclays PLC now owns 112,727 shares of the medical instruments supplier’s stock valued at $11,142,000 after acquiring an additional 84,923 shares during the period. Van ECK Associates Corp bought a new position in Merit Medical Systems during the third quarter valued at approximately $718,000. Fisher Asset Management LLC boosted its holdings in Merit Medical Systems by 3.2% in the third quarter. Fisher Asset Management LLC now owns 221,690 shares of the medical instruments supplier’s stock worth $21,910,000 after purchasing an additional 6,837 shares during the last quarter. JPMorgan Chase & Co. grew its position in Merit Medical Systems by 85.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 575,946 shares of the medical instruments supplier’s stock worth $56,921,000 after purchasing an additional 265,648 shares during the period. Finally, AMI Asset Management Corp raised its stake in Merit Medical Systems by 28.7% during the 4th quarter. AMI Asset Management Corp now owns 33,041 shares of the medical instruments supplier’s stock valued at $3,196,000 after buying an additional 7,367 shares during the last quarter. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Merit Medical Systems

In related news, CFO Raul Jr. Parra sold 29,646 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the transaction, the chief financial officer now owns 16,361 shares in the company, valued at $1,603,705.22. The trade was a 64.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director F. Ann Millner sold 12,500 shares of Merit Medical Systems stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the transaction, the director now owns 32,391 shares of the company’s stock, valued at $3,289,306.05. The trade was a 27.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.